Evaluating Personalized (N-of-1) Trials in Rare Diseases: How Much Experimentation Is Enough?

导出 LinkOut

翻译打印收藏纠错

作者： Ken,Cheung ^[1] ; Hiroshi,Mitsumoto ^[2]

作者单位： Mailman School of Public Health, Columbia University, New York City, New York, United States of America. ^[1] Columbia University Irving Medical Center, Columbia University, New York City, New York, United States of America. ^[2]

关键词 ALS heterogeneity of treatment effects (HTE)minimally clinically important heterogeneity patient-centered research rare diseases sample size formulae

DOI 10.1162/99608f92.e11adff0

PMID 38283317

发布时间 2024-10-23

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览0

Harvard data science review

2022年2022卷Spec Iss 3期

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Evaluating Personalized (N-of-1) Trials in Rare Diseases: How Much Experimentation Is Enough?

Harvard data science review

相似文献

Harvard data science review

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Evaluating Personalized (N-of-1) Trials in Rare Diseases: How Much Experimentation Is Enough?

Harvard data science review

相似文献

Harvard data science review

相关期刊

检索历史清除